Sanofi's hoped-for anti-obesity blockbuster will go before the FDA advisory committee on June 13, it says here. This application has been delayed before, so the tension will be mounting among the Sanofites all through the summer.
Couple of interesting things to consider:
Second, this report by Decision Resources notes that Acomplia will become the 'gold standard' in weight loss treatment--despite side effects of depressiona and anxiety among users.
Hold on a second: depression and anxiety have caused havoc for Roche's Tamiflu and Lilly's Strattera (both linked to reports of suicide). I can't see the press giving Sanofi a free pass on this issue if those side effects are in any way significant.